![]() |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Lista de Categorias
AlcoolismoAlzheimer E ParkinsonAnalgésicosAnti-InflamatóriosAnti-helmÃnticosAnti-viraisAntialérgicosAntibióticosAnticoncepcionaisAnticonvulsivantesAntidepressivosAntifúngicosArtriteAsmaCancroCirúrgiaColesterolCuidados Da PeleCuidados Para Los OjosDiabetesDisfunção EréctilDiuréticosDoenças CardiovascularesEnxaquecasH I VHipertensão ArterialObesidadeOsteoporosePerturbações MentaisPerturbações NeurológicasRelaxantes MuscularesSaúde FemininaSaúde MasculinaTrato GastrointestinalTrato RespiratórioTrato Urinário 04 May 2012 14:50:50
Should Congress Allow FDA To Give Reversible Drug Approvals?Should Congress Allow FDA To Give Reversible Drug Approvals? Forbes Avik and I run the gamut, talking about everything from Vytorin to Avastin, and I think the result is at least interesting. in all the hurly burly I never called for any of these drugs to be withdrawn â I did call to do the science to identify the ...
30 Apr 2012 22:41:49
Why the Dow's Barely Budging This MorningWhy the Dow's Barely Budging This Morning msnbc.com Merck rose more than 2% after a court ruling that confirmed the drugmaker's patents on Zetia and Vytorin . Generic-drug maker Mylan had sought to produce a copy of the drugs prior to their expiration in 2017. With Merck already facing patent-cliff ...
30 Apr 2012 19:13:58
Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks;Merck wins patent fight on Zetia, Vytorin ; Fitch warns of 'pure pharma' risks; FiercePharma Article Follow FiercePharma » A US court upheld Merck's ($MRK) patent on the active ingredient ezetimibe, marketed as the cholesterol-lowering Zetia and in the combo cholesterol pill Vytorin . Report » Fitch Ratings says drugmakers that focus purely ... Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute Merck wins pharmaceutical sales rights to two blockbuster drugs through 2017
30 Apr 2012 18:48:40
What Could Move the Dow This WeekWhat Could Move the Dow This Week msnbc.com Meanwhile, rival Merck got some good news Friday, when a court upheld a patent on its cholesterol drugs, Zetia and Vytorin . The two drugs contributed more than $1 billion in sales in the company's first quarter. Meanwhile, Kraft baffled market-watchers ...
30 Apr 2012 14:51:36
Wall Street Poised For Early Profit Taking - U.S. Commentary ABC News Wall Street Poised For Early Profit Taking - U.S. Commentary RTT News A US court has ruled that a patent for drug maker's Zetia and Vytorin cholesterol drugs is valid. Spain continues to face economic trouble. New data released last week showed that the country's unemployment rate is sitting above 24 percent - reaching ... Stocks In The Red Monday Morning; Barnes & Noble Up 60% -- U.S. Commentary30 Apr 2012 05:35:16
Investor Medical Waves - (VVUS, MRK, MYL, AMPE)Investor Medical Waves - (VVUS, MRK, MYL, AMPE) Galaxy Stocks According to the company, sales of ZETIA were $614M in the 1Q 2012, while Vytorin's sales were $444M during the period. Investors attention could be on Mountain View, California-based VIVUS Inc. (Nasdaq:VVUS) on Monday, after the biopharmaceutical ...
28 Apr 2012 00:31:49
US Judge Upholds Validity Of Merck's Vytorin PatentUS Judge Upholds Validity Of Merck's Vytorin Patent Wall Street Journal s (MRK) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years. In an opinion released Friday, US District Judge Jose Linares in federal court in Newark, NJ, said the patent for was valid and ... Merck Wins Vytorin Patent Infringement Suit Against Mylan Merck Wins U.S. ZETIA(R) (ezetimibe) VYTORIN (R) (ezetimibe simvastatin ... Merck Wins Two Patent Lawsuits
27 Apr 2012 13:44:11
Merck profit rises 67% on lower costs Bloomberg Merck profit rises 67% on lower costs MarketWatch ... and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin . Merck Beats by a Penny; Affirms View - Analyst Blog Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call Transcript Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows |
|
Choose Your language:
Pesquisa no site:
Testemunhos
Caro Senhor,
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mais vendidos|Política|Questões Mais Frequentes|Testemunhos|Contacte-nos|Sitemap |
|
|
|
|
| |